Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer.
作者： J Zekri , M Mokhtar , S M Karim , T Darwish , M Al-Foheidi
DOI: 10.31768/2312-8852.2015.37(2):146-150
关键词:
摘要: BACKGROUND Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients advanced/metastatic HER2 positive breast cancer (HER2(+)BC) after progression on trastuzumab based therapy. Here we report our experience lapatinib therapy this setting. MATERIAL AND METHODS 67 consecutive received 58 (86.6%) + (LC), 7 (10.4%) agents and 2 (3.0%) as single agent lapatinib. Data was collected from patients' records retrospectively. RESULTS Objective response to 64 evaluable 64.0% all who LC. Median free survival overall were 10 27 months 17 LC, respectively. 16 (24.0%) had dose delay > 1 week and/or reduction. CONCLUSION an effective treatment women HER2(+)BC prior exposure trastuzumab. It yields meaningful rates, survival. Some require adjustments.
sci-hub.st 参考文章(23)
A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high risk features and poor outcome Ecancermedicalscience. ,vol. 4, pp. 167- 167 ,(2010) , 10.3332/ECANCER.2010.167
Miguel Martin, Jacques Bonneterre, Charles E. Geyer, Yoshinori Ito, Jungsil Ro, Istvan Lang, Sung-Bae Kim, Caroline Germa, Jennifer Vermette, Kenneth Wang, Kongming Wang, Ahmad Awada, A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer European Journal of Cancer. ,vol. 49, pp. 3763- 3772 ,(2013) , 10.1016/J.EJCA.2013.07.142
P. Saip, Y. Eralp, F. Sen, H. Karaca, M. Ozkan, B. Cetin, M. Benekli, M. Kucukoner, A. Isikdogan, O. Un, G. Basaran, H. Onur, Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. The Breast. ,vol. 22, pp. 628- 633 ,(2013) , 10.1016/J.BREAST.2013.07.048
Tobias Botrel, Otávio Clark, Luciano Paladini, Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis Core Evidence. ,vol. 8, pp. 69- 78 ,(2013) , 10.2147/CE.S50474
N Fleeman, A Bagust, A Boland, R Dickson, Y Dundar, M Moonan, J Oyee, M Blundell, H Davis, A Armstrong, N Thorp, Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis Health Technology Assessment. ,vol. 15, pp. 1- ,(2011) , 10.3310/HTA15420
Angelo Di Leo, Henry L. Gomez, Zeba Aziz, Zanete Zvirbule, Jose Bines, Michael C. Arbushites, Stephanie F. Guerrera, Maria Koehler, Cristina Oliva, Steven H. Stein, Lisa S. Williams, Judy Dering, Richard S. Finn, Michael F. Press, Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 26, pp. 5544- 5552 ,(2008) , 10.1200/JCO.2008.16.2578
E Brain, N Isambert, F Dalenc, V Diéras, J Bonneterre, K Rezai, M Jimenez, F Mefti-Lacheraf, E Cottura, P Tresca, L Vanlemmens, C Mahier-Aït Oukhatar, F Lokiec, P Fumoleau, Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2 British Journal of Cancer. ,vol. 106, pp. 673- 677 ,(2012) , 10.1038/BJC.2011.591
Wolfgang Janni, Tomasz Sarosiek, Boguslawa Karaszewska, Joanna Pikiel, Elzbieta Staroslawska, Piotr Potemski, Christoph Salat, Etienne Brain, Christian Caglevic, Kathryn Briggs, Michelle DeSilvio, Luca Marini, Christos Papadimitriou, A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 143, pp. 493- 505 ,(2014) , 10.1007/S10549-013-2828-Z
Bulent Cetin, Mustafa Benekli, Faysal Dane, Cem Boruban, Mahmut Gumus, Berna Oksuzoglu, Mehmet A. Kaplan, Gulnihal Tufan, Alper Sevinc, Ugur Coskun, Suleyman Buyukberber, Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Breast Care. ,vol. 8, pp. 67- 70 ,(2013) , 10.1159/000346829
Bing-He Xu, Ze-Fei Jiang, Daniel Chua, Zhi-Min Shao, Rong-Cheng Luo, Xiao-Jia Wang, Dong-Geng Liu, Winnie Yeo, Shi-Ying Yu, Beth Newstat, Alka Preston, Anne-Marie Martin, Hai-Dong Chi, Li Wang, Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients Chinese Journal of Cancer. ,vol. 30, pp. 327- 335 ,(2011) , 10.5732/CJC.010.10507